Miserocchi Elisabetta, Modorati Giulio, Galli Laura, Rama Paolo
Department of Ophthalmology and Visual Sciences, San Raffaele Scientific Institute, Milan, Italy.
Am J Ophthalmol. 2007 Oct;144(4):547-51. doi: 10.1016/j.ajo.2007.06.001. Epub 2007 Aug 9.
To compare the efficacy of one-year treatment with valacyclovir vs acyclovir in preventing recurrence of the herpes simplex virus (HSV) eye disease.
Prospective, randomized, clinical trial pilot study.
Fifty-two immunocompetent patients with a history of recurrent ocular HSV disease were treated at the Ocular Immunology Service, San Raffaele Hospital, Milan, Italy. Twenty-six patients were randomized to the valacyclovir group (one 500 mg tablet daily), and 26 patients were randomized to the acyclovir group (one 400 mg tablet twice daily). The recurrence rate of ocular HSV disease during 12 months of treatment and drug-related side effects were monitored.
Recurrence of any type of ocular HSV disease during the 12-month treatment period was 23.1% in the valacyclovir group, compared with 23.1% in the acyclovir group. No difference between the two groups was observed regarding the nature, frequency, or severity of adverse events. The most frequent adverse events were nausea and headache.
One-year suppression therapy with oral valacyclovir (500 mg tablet daily) was shown to be as effective and as well tolerated as acyclovir (400 mg tablet twice daily) in reducing the rate of recurrent ocular HSV disease.
比较伐昔洛韦与阿昔洛韦一年治疗预防单纯疱疹病毒（HSV）眼病复发的疗效。
前瞻性、随机临床试验初步研究。
52例有复发性眼部HSV疾病史的免疫功能正常患者在意大利米兰圣拉斐尔医院眼科免疫科接受治疗。26例患者随机分为伐昔洛韦组（每日1片500毫克），26例患者随机分为阿昔洛韦组（每日2次，每次1片400毫克）。监测治疗12个月期间眼部HSV疾病的复发率和药物相关副作用。
伐昔洛韦组在12个月治疗期间任何类型的眼部HSV疾病复发率为23.1%，阿昔洛韦组为23.1%。两组在不良事件的性质、频率或严重程度方面未观察到差异。最常见的不良事件是恶心和头痛。
口服伐昔洛韦（每日1片500毫克）进行一年抑制治疗在降低复发性眼部HSV疾病发生率方面与阿昔洛韦（每日2次，每次1片400毫克）一样有效且耐受性良好。
